摘要
目的：观察大黄蛰虫丸对改善兔肾动脉粥样硬化性狭窄,减轻肾脏病理改变及其对炎症相关细胞因子的影响。方法：将健康新西兰大耳白兔35只,随机分为模型组、中药中剂量组、中药高剂量组、对照组、空白组。模型组、中药组、对照组普通饲料喂养1周后行左肾动脉银夹缩窄术造模。术后各组予高脂饲料喂养12周,中药组予大黄蛰虫丸灌胃12周,西药组予辛伐他汀灌胃12周,模型组、空白组每天灌服等量蒸馏水,灌胃12周。造模术12周后处死家兔取主动脉、肾动脉和肾脏观察其病理形态学改变,通过图像分析系统(Motic Images Advanced 3.0)测量内膜、中膜厚度和管腔面积,计算肾动脉的狭窄程度。观察各组胆固醇、甘油三酯、低密度脂蛋白、高密度脂蛋白、肾功能变化,用双抗体夹心酶联免疫吸附(ELISA)检测法对TNF-α、IL-1β进行测定。结果：1.成功建立了粥样硬化性肾动脉狭窄缺血兔模型；2.与模型组比较,各治疗组肾动脉狭窄程度和肾动脉壁内、中膜的增厚明显减轻(P<0.01),大黄蛰虫丸各组肾间质纤维化程度轻于模型组(P<0.05)；大黄蛰虫丸可明显降低模型兔胆固醇和低密度脂蛋白的水平(P<0.05),降低炎症因子TNF-α、IL-1β的水平(P<0.05)；与模型组、辛伐他汀组比较,大黄蛰虫丸高剂量组能明显降低血肌酐值(P<0.05)。结论：大黄蛰虫九可通过抗炎和降血脂而发挥一定的抗动脉硬化的作用,减轻肾脏损害。提示其对粥样硬化血管狭窄引起的肾缺血有一定的预防和治疗作用,为中药防治动脉粥样硬化性’肾动脉狭窄(ARAS)提供了实验依据。
Objective To observe the effects of Dahuang Zhechong Pill on improvement of renal atherosclerosis, pathological changes and inflammatory factor in rabbit. Methods Thirty five healthy New-Zealand white rabbits were randomly divided into groups control, model, high-dose, middle-dose of Dahuang Zhechong Pill (DZP) and blank. Before the silver clip tightening surgery of establish left kidney artery ligation models, the rabbits in model group, TCM group(treated by DZP) and control group(treated by Simvastation) were feed with ordinary food for one week. After the operation, all rabbits were feed with high fatty food for 12 weeks. At the same time, the TCM groups given Dahuang Zhechong Pills in high, medium doses, respectively by intragastric administration.The control group were given Simvastation. The model and the blank groups were given equal amount of distilled water. Aftre 12 weeks, the aorta, renal artery and renal pathological morphology were observed by image analysis system (Motic Images Advanced 3.0). The thickness and area of tunica intima and tunica media were measured. In addition, the sections were analyzed for renal artery stenosis.The levels of serum cholesterol (TC), triacylglycerol (TG), low density lipoprotein(LDL),high density lipoprotein (HDL), renal function were measured. ELISA was used to measure the contents of TNF-a、IL-1β. Results 1. Atherosclerotic renal artery stenosis-caused renal ischaemia models were established successfully in rabbit. 2. Compared with the model group, the renal artery stenosis and thickness of renal artery tunica media in treated groups were decreased significantly (P<0.01). At the same time, the degrees of renal interstitial fibrosis were decreased (P<0.05) in TCM groups compared with the model group. The levels of serum cholesterol (TC) and low density lipoprotein(LDL) were declined in TCM group(P<0.05). The contents of TNF-a、IL-1βwere decreased (P<0.05). Compared with the model group and the control group, the blood creatinine in the high-dose group of DZP was decreased significantly (P<0.05). Conclusion Dahuang Zhechong pill suppresses the development of atherosclerosis and reduce kidney damage by modulating blood lipid and anti-inflammation.It is suggested that DZP is beneficial for prevention and treatment on AS-caused renal ischemia and provide some experimental basis for the prevention of atherosclerotic renal artery stenosis (ARAS).
引文
[1] Shafique S , Veixoto AJ . Renal artery stenosis and cardiovascular risk[J].J Clin Hypertens , 2007, 9(3): 201-208
[2] 王钢,陈以平,邹燕勤.现代中医肾脏病学[M].北京:人民卫生出版社,2003:751
[3] Van J aarsveld BC , Krijnen P , Pieterman H , et al . The effect ofballoon angioplasty onhypertension in at herosclerotic renal2arterystenosis[J] . N Engl J Med, 2000, 342(9): 1007- 1014.
[4] Textor SC , Wilcox CS. Renal artery stenosis : a common , treatablecause of renal failure ?[J] Annu Rev Med, 2001,52 (3): 421-442.
[5] Gill KS , Fowler RC. At herosclerotic renal arterial stenosis : clinicaloutcomes of stentplacement for hypertension and renal failure [J] . Radiology, 2003, 226(5): 821-826.
[6] 徐叔云,卞如镰,陈修.药理实验方法学[M].第3版.北京:人民卫生出版社,2008,1049-1050
[7] 王海燕.动脉粥样硬化性肾动脉狭窄-呼唤跨学科的研讨与合作〔]J.中华内科杂志,2005,44(11):801-803
[8] 张晓英.动脉粥样硬化与漫性缺血性肾病[J].临床肾脏病杂志,2002,23)(:149-152
[9] 刘必成,汤日宁.慢性缺血性肾病的诊治进展[J].郑州大学学报(医学版),2008,43(1):5-8
[10]毕增棋,郑法雷.慢性缺血性肾脏疾病的诊断与治疗[J].中华内科杂志,2000,39(6):418-420
[11] Ohashi R .Kitaraura H, Yamanaka Nl[J].JAm SocNephrol, 2000,11 (1): 47 - 56
[12] Thomas CL ,Yang B, Wagner BE, et[J]. NephrolDialTransplant, 1998,13(9):2216-2226
[13] Liu YQ ,Zhang WD ,Cuo AH ,et al. Expression and function ofTNF - a in.membranoproliferative glonierulonephritis. Zhong Guo Xian Dai Yi Xue Za Zhi ,2002 ,12 (6) : 20.
[14] 李玲,邹万忠,张波,等.病理性因素对体外肾小管上皮细胞表型转化的影响.中华肾脏病杂志,2003,19(1):1.
[15] Panzer U , Thaiss F ,Zahner G, etal. Monocyte chemoattractant protein-land osteopontin differentially regulate monocytes recruitment in experi-mental glomerulonephritis
[16] 张大宁.中医补肾活血法的研究[M].北京:中国医药科技出版社,1997,25-28
[17] 张勉之,短惠军,韩彩丽.虫草地黄活血汤对动脉粥样硬化性肾损害的实验研究[.中国中西医结合肾病杂志,2002,3(12):695-698
[18] 韩彬.益肾通络汤治疗慢性缺血性肾病72例临床观察[J].中医药导报,2006,10(12):65-67
[19] 潘丽萍,王稀.丹参川常漆治疗慢性缺血性肾病临床疗效观察和对血流参数等的影响[J].中国实用内科杂志,2008,28,(12):55-58
[20] 陈星华,徐万纹.杏丁注射液治疗缺血性肾病的疗效观察[J].时珍国医国药,2080,19(1)2:3059-3060
[21] 饶向荣,张南南.动脉粥样硬化性’肾动脉狭窄中医证候初探[J].中国中西医结合肾病杂志,201,011(2):125-127
[22] 周建英,钱丽,申冬珠,等.大黄醇提片降脂与抗动脉粥样硬化的研究[J].山东中医药大学学报,197921(1):107-108
[23] Abel, SekiT, NoguchiH, etal.Galloy lesters from rhubarbare potent inhibitors of squalene epoxidase, a keyenzyme in cholesterol biosynthesis[J].PlantaMed, 2000, 66 (8) :753-756
[42] 文川,徐浩,黄启福,等.活血中药对Apo E基因缺陷小鼠血脂及动脉粥样硬化斑块炎症反应的影响[J].中国中西医结合杂志,2005,25(4):34-51
[25] Park WH , Hong MY , Chung KH , etal . Effect s of traditional herbal medicine , Hwaotang , on at heroscle-rosis using the spontaneous familial hypercholes2terolemia model , Kurosawa and Kusanagi-hypercholesterolemicrabbits and the venous thrombosis rats U]lPhytotherRes ,2005,19(10): 846 '
[26] 王玉红,程霞,陈光辉地黄化学成分研究及治疗心血管疾病的临床应用[J].中西医结合心脑血管病杂志,2009,7(12):1451-1456
[27] 梁进权,实穗卿,王宁生,等.水蛙、蛇虫配伍的抗凝血和杭血小板聚集的作用[J].中药材,2009,23(9):1347-1350
[28] 梁进权,实穗卿,王宁生,等.水蛙、蛇虫药对对血疥模型大鼠血液流变性的影响[J].中药药理与临床,2008,24(3):71-75
[29] 蒋坤.大黄蛰虫丸抗乙型肝炎肝纤维化疗效观察[J].现代中西医结合杂志,2006,15(6):732
[30] 冯金铭,胡日旺.大黄蛰虫九联合凯西莱治疗酒精性肝纤维化36例临床观察[J].山西职工医学院报,2004,14(4):49
[31] 陆灵光,李健波.大黄蛰虫胶囊联合陈夏六君子九治疗脂肪肝肝炎效果观察[J].国际医药卫生导报,2006,12(11):77
[32] 黄山,荣蓉.活血化淤药对血脂的影响[J].中国误诊学杂志,2007,7(3):481
[33] 高虹.大黄蛰虫丸治疗室性早搏83例临床体会[J].中国中医急症,2007,16(11):1408
[34] 高中,陈汝兴,顾明昌,等.大黄蛰虫九治疗脑出血急性期的临床观察[J] 上海中医药杂志，2005，39(3):14
[35] 卢立广.大黄蛰虫丸加减治疗支气管哮喘46例[J]浙江中医杂志,2004,39(9):831.
[36] 杨韶华,王祥生,曹务礼.大黄蛰虫丸治疗肾病综合征并急性肾功能衰竭疗效观察[J].中国中医急症,2005,14(9):843
[37] 高鹏翔,徐丹,高鹏武.大黄蛰虫九治疗闭经181例的临床观察[J]贵阳中医学院学报,2006,28(1):22
[38] 古春青.[318古春青.少腹逐淤汤合大黄蛰虫丸加减治疗子宫脏瘤98例疗效观察[J].中国社区医师,2007,23(22):51
[39] 刘秀峰,陈丽笙,何珍.大黄蛰虫丸治疗子宫腺肌病30例观察[J].实用中医药杂志,2004,20(2):64
[40] 叨肖发喻.加味逍遥散内服配合大黄蛰虫丸外敷治疗乳腺增生70例[J].四川中医,2008,26(1):94
[41]徐泽杰,张希.大黄蛰虫九加减治疗漫性前列腺炎107例[J].四川中医,2004,22(1):13
[42]牛桂芳.大黄蛰虫丸治疗重度座疮疗效观察[J].中国皮肤性病学杂志,2004,18(6):369
[43]江玉娟,司秋菊.大黄蛰虫丸的临床应用及研究进展[J].时珍国医国药,2009,20(5):1215-216
[44]贾运乔等.大黄蛰虫丸对动脉粥样硬化作用的研究[J].河北中医药报,2009,124():4
[45]黄众明,沈士芳.大黄蛰虫九治疗高脂血症的临床观察及实验研究[J].中西医结台杂志,198;99(19):589-592
[46]廖福龙.活血化疥药物药性的血液流变学研究[J],中国中西医结合杂志.1986,6(2):103
[47]李静莉,刘俊田,苟伟,等.大黄蛰虫丸抗家兔动脉粥样硬化机理研究【JJ.中国实验方剂学杂志.2006,12(5):32-34
[48]孙伟,曾安平,盛梅笑,高冲,何伟明.大黄蛰虫九延缓慢性肾小球疾病进展的临床分层研究口1.辽宁中医杂志.2004,31(11):887-889
[49]杨韶华,王祥生,曹务礼.大黄蛰虫九治疗肾病综合征并急性肾功能衰竭疗效观察[J].中国中医急症.2005,14(9):843-844
[50]王选平.水蛙对实验性高脂血症家免胆同醇,甘油三醋,6-酮-PGZFa及XTBZ的影响[J].中西医结合杂志.1988:8(10):636
[51]游金根.大黄治疗高脂血症39例临束观察〔]J.福建中医药.1983,14(1):91.
[52]王巍.活血化癖药调脂作用的研究(初报).中西医结合杂志[J].198;881()9:620-622
[53]魏连波、马志刚.大黄度虫九对大鼠肾间质纤维化及TGF-日lRnNA表达的影响中国中西医结合杂志2003年6月第1卷基础理论研究特集115-116
[54]韩晓静,苏珍枝.大黄蛰虫丸抗实验性大鼠肝纤维化的作用机制[J].医药产业资讯,2060,38)(:28-29
[55]姬媛媛,刘俊田,李静莉,等.大黄蛰虫丸拆方对动脉硬化家兔血管平滑肌细胞增殖与凋亡的影响IJJ.中国中西医结合杂志,2006,26(10):913-915
[56」李静莉,刘俊田,苟伟,等.大黄蛰虫九对动脉粥样硬化模型家兔血管平滑肌细胞的影响[J].中成药,2006,28(10):1470
[75]戴高中,顾明昌,袁灿兴.大黄蛰虫丸对大鼠脑细胞NOTET-oAc含量的影响[J].辽宁中医杂志,2006,33(4):492
[58]孙伟,朱查查,曾安平,等.大黄蛰虫九对改良阿霉素肾病肾硬化大鼠模型作用的实验研究[J].中成药,2006,28(1):81
[59]陈继红,孙伟,高坤,等.大黄蛰虫丸对阿霉素肾硬化大鼠血栓素BZ、6-酮-前列腺素F的影响[J].中国中医药信息杂志,2007,14(10):26
[60]孙伟,陈继红,高坤,等.大黄蛰虫丸对阿霉素肾硬化大鼠系膜基质增生抑制作用的实验研究[J].江苏中医药,2008,40(1):77
[61]韩晓静,苏珍枝.大黄蛰虫九杭实验性大鼠肝纤维化的作用机制[J].医药产业资讯,2006,3()8:82
[62]周阿高,张勇,孔德云,等.大黄蛰虫丸对荷瘤小鼠免疫作用的研究[J].中成药,2006,28(12):1772-1775
[63]体丽,李吉来,许俊杰,等.大黄蛰虫丸对实验性血检及体外血小板聚集性的影响[J].中成药,1992,14(4):29-30
[64]体丽,陈育尧,黄添友.大黄蛰虫丸对血癖模型大鼠纤溶活性及血小板内环核普酸含量的影响【]J.中药药理与临床,1995,(5):8-10
[65]张殿增,王美纳,赵东科,等.大黄蛰虫丸对实验性血栓形成和xTBZ/PGIZ比值的影响[J].西安医科大学学报,1993,24(4):319-322.
[66]刘青云,彭代银,周逸平,等.大黄蛰虫丸对大鼠血液流变性的影响[J].安徽中医学院学报,1991,01(2):58-60
[67]张殿增,王美纳,年培伦.大黄蛰虫丸对血癖证大鼠微循环的影响[J].西安医科大学学报,1994,15(1):37-39,44
[68]黄众明,沈士芳.大黄蛰虫丸治疗高脂血症的临床观察及实验研究[J].中西医结合杂志,1989,9(10):589-592
[69]谢世平,封银漫.大黄蛰虫丸对实验性脑缺血影响的研究[J].河南中医,1997,17()5:韶2-238.
[70]高峻枉,时振生.大黄蛰虫九治疗大鼠慢性肾功能衰竭的实验研究[J].中国中医药科技,1998,5(2):73-74
[71]川杨永宗.动脉粥样硬化实验研究模型百年回溯[J].中国动脉硬化杂志,2008,16(1):2925-930
[72]董怡,黄咏红,陈为民,等.犬慢性缺血性肾病模型的建立及超声造影定量分析可行性评价[J].中国医学计算机成像杂志,2009,25(4):381-354
[73)刘毅,李志楔,雷霄,等.兔腹主动脉粥样硬化模型的建立及评估方式[J].南方医科大学学报,200;929(9):1874-1876
[74]田枫,张阔,康爱君.12月龄PAoe-/-动脉粥样硬化小鼠心脏、肝脏和肾脏病变的特点[J].中国老年学杂志,20-0年30(1):190-194
[75]Ohashi R,Mu H, Yao Q, et al . Cellular and molecular mechanis ms ofatheroscler osiswithmouse models[J]. Trends CardiovascMed,2004,14(5):187-190
[76]Wilson D B, Mostafavi K, Craven T E, et al. Clinical course of mes-enteric artery stenosisin elderlv AmericansTJ1. Arch Intern Med2006.166 (19): 2095 - 2100(2):58-60
[77]黄朝晖,吴雄飞,赵洪雯,等.PAoE-/-小鼠肾动脉狭窄及肾损害特点观察[J].第三军医大学学报,2007,29(19):1844-1846
[78]吴明远,李令根,赵钢等.家兔股动脉粥样硬化闭塞症模型的制作[J].中国中西医结合外科杂志,2004,10(1):29-31
[79]沈长银,石蓓,赵然尊等.兔颈动脉粥样硬化狭窄动物模型的制备[J].四川大学学报(医学版)2009,40(5):923-926
[80]张军平,许颖智,李良军.实验性动脉粥样硬化模型复合建模的方法及评价[J].中国比较医学杂志,2009,19(1):41-45
[81]Massy Z, Guijarro C. Statins: effects beyond cholesterol lower ing[J]. Nephrol Dial Transplant, 2001,16: 1738-1741
[82]Libby P,Current concep ts of the pathogensis of the acute coronary syn-dromes[J].Circulation, 2001,104:365-372
[83]VermaS, Anderson TJ. Fundamentals of endothelial function for theclinical cardiologist [J].Circulation, 2002,105: 546-549
[84]贺礼荣.早期使用辛伐他汀对2型糖尿病患者动月扣硬化的影响[J].内科,2009,4,4)(:529-513
[85]张红霞,刘剑刚.动脉粥样硬化发病机制和炎症反应关系研究进展[J].中国心血管杂志2005,01(10):385-387
[86]Mullenix PS, Andersen CA, StarnesBW. Atherosclerosis as inflamma-tion[J]. Ann Vase Surg,2005,19(1): 130-138
[87]Garovic VD, Textor ClRenovascular hypertension and ischemic ne-phropathy [J] .Circulation,2005,112 (9): 1362-1374
[1] Jacobson HR. Ischemic renal disease. An overlooked clinical entity? [J]. Kidney Int,1988, 34: 729-743.
[2] Zocali C, Mallamaci F, Finocchiaro P, et al. Atherosclerotic renal artery stenosis: Epidemiology, cardiovascular outcomes, and clinical p redictidn rules [J]. J Am Soc Nephrol,2002, 13 (Suppl):S179-S183.
[3]Conlon PJ, Oriordan ED ,Kalra PA.New insights into the epidemiologic and clinicalmanifestations of atherosclerotic renovascular disease. Am J Kindey Dis, 2000, 35: 573-578
[4] Mailous L, Napolitano B, Belluic AG, et al. Renal vascular disease causing end stage renaldisease, incidence, clinical correlates, and outcomes: A 20-year clinical experience[J],Am J KindeyDis, 1994, 24: 622-629.
[5] Fatica RA, Port FK, Young EW. Incidence trends and mortality in end stage renal disease attributed to renovascular disease in the Unitied States. Am J Kindev Dis. 2001. 1187-1190
[6] 周莉,付平,沙朝晖,等.缺血性肾病与杭凝治疗[J].临床荟苹,2006,21(6):346-438
[7] Textor SC. Pathophysiology of renal failure in renovascular disease [J]. Am J Kindey Dis,1994, 24: 642-651.
[8] Van de VenPJG, Beutler JJ, Kaatee R, et al. Angiotensin converting enzyme inhibitor induced renal dysfunction in atherosclerotic renovascular disease[J]. Kidney Int, 1998, 53: 986-993
[9] Makanjuola AD, SuresliM, Laboi P, et al. Proteinuria inatherosclerotic renovascular disease,1999, 92: 515-518
[10] Crowley JJ, Santos RM, Peter RH, et al. Progression of renal artery ste-nosis in patietsundergoing cardiac catheterization [J] .Am Heart J, 1998, 136: 913-918
[ll] Leertouwer TC, Pattynama PM, Van den Berg-HuysmansA: Incidental renal artery stenosis in'peripheral vascular disease: A case for treat-ment? Kindey Int, 2001, 59: 1480-1483.
[12 ]Dean RH, Kieffer RW, Smith BM, et al. Renovascular hypertension: Anatomic and renalfunction changes during drug therapy [J]. ARCH Surg, 1981, 116: 1408-1415
[13] SchreiberMJ, PohlMA, NorvickAC. The natural history of atheroscle-rotic and fibrous renalartery disease [J]. Urol Clin North Am, 1984,11: 383-392
[14] Cap sMT, Zierler RE, Polissar NL, et.al. Risk of atrophy in kidneys with.atheroscleroticrenal artery stenosis [J]. Kindey Int, 1998, 53: 735-742
[15] Wright JR, DuggalA, Thomas R, et alClinicopathologicalcorrelations in.Mop sy-p rovenatherosclerotic nephopathy: Imp lications for renal functional outcome inatherosclerotic renovascular disease[J], Nephrol Dial Trans plant, 2001,16: 765-770
[16] Conlon PJ, Athirakul K, Kovalik E, et al. Survival in renal vascular disease[J]. J Am Soc Nephro,1998,9:252-256
[17]Erbsloh-Moller B, DumasA, Roth D, et al. Furosemide 131-hippuran renography after angiotension-convert ing enzyme inhibition for the diagnosis of renovascular hypertension[J]. Am J Med,1991,90:23-29
[18]Ikee R, Kobayashi S, HemmiN, et al. Correlation between the resistive index by Dopp ler ultrasound and kidney function and histology[J]. Am J Kindey Dis,2005,46:603-609
[19]Rabbia C, Valp reda S. Dup lex scan sonography of renal artery steno-sis. Int, Angiol, 2003,22:101-115
[20]Schoenbery SO, Knopp MV, Londy F, et al. Morphologic and function-almagnetic resonance imaging of renal artery stenosis. Amultireadertricenter study[J]. J Am Soc Nephrol, 2002,13:158-169
[21]Park S, Jung JH, Seo HS et al. The p revalence and clinical predictors of atherosclerotic renal artery stenosis in patients undergoing coronaryangiography [J]. HeartVessels,2004, 19:275-279
[22]Jensen G, Zachrisson BF, Delink et al. Treatment of renovascular hy-portens ion:one year results of renal angiop lasty [J]. Kindey Int,1995,48:1936-1945
[23]Van de Ven PJ, Kaatee R, Beutler JJ, et al. Arterial stening and balloon angiop lasty ostial atherosclerotic renovascular disease[J]. A randomized trial. Lancet,1999,353: 282-286
[24]Van Jaarsveld BC, Krijnen P, Pieterman H, et al. For the Dutch Renal Artery Stenosis Intervention Cooperative Study Group:The effect of balloon angiop lasty in hypertension in atherosclerotic renal artery stnosis[J]. N Engl J Med,2000,342:1007-1017
[25]Rademacher J, Chavan A, Bleck J, et al. Use of Dopp lerultrasonogra phy to p redict the outcome of therapy for renal artery stenosis[J]. N Engl J Med,2001,344:410-417
[26]王梅 老年缺血性肾脏病的诊治进展[J].中国实用内科杂志,2007,27(1)：59-61
[27]Muray S, MartinM, AmodeoML, et al. Rap id decline in renal functionreflects reversibility and predicts the outcome after angiop lasty in renalartery stenosis [J]. Am J Kindey Dis, 2002,39:60-66
[28]Greco BA, Breyer JA. Atherosclerotic ischemic renal disease[J]. Am J Kindey Dis,1997, 29:167-187
[29]费玉明,徐文姬,卜惠姣等,活血通脉胶囊治疗老年人缺血性肾脏病[J].浙江中西医结合杂志,2005,15(3)：141-143
[30]姜平,于志勇.疏血通治疗慢性缺血性肾病疗效观察[J].山东医药,2004,44(22)：9
[31]魏丹霞 慢性缺血性肾病-中老年人不易解释氮质血症的中医证候分布研究[J].云南中医学院学报,2007,27(2)：31-33